BOS reports Q3 2025 results, hosts video conference call on November 25.

• BOS to release Q3 2025 financial results on November 25, 2025 • Earnings call to be held at 8:30 a.m. EST • Meeting link: https://us06web.zoom.us/j/84586132530?pwd=MR8FSUWdKBSvsBtc0KTHYDZRZQiIcb.1 • Recording available on BOS website: boscom.com

BOS Inc. is set to release its Q3 2025 financial results on November 25, 2025, with an earnings call scheduled for 8:30 a.m. EST. The meeting will be held virtually and can be accessed via the following Zoom link: [https://us06web.zoom.us/j/84586132530?pwd=MR8FSUWdKBSvsBtc0KTHYDZRZQiIcb.1](https://us06web.zoom.us/j/84586132530?pwd=MR8FSUWdKBSvsBtc0KTHYDZRZQiIcb.1). A recording of the call will be available on the BOS website at [boscom.com](https://boscom.com).

The Q3 earnings report is expected to provide insights into the company's financial performance during the quarter, including revenue, earnings, and other key financial metrics. Investors and financial professionals will be closely monitoring the results to gauge the company's operational health and strategic direction.

BOS has been actively involved in various clinical trials and developments in the healthcare sector. The company's pipeline includes innovative treatments for severe infectious diseases, as well as targeted therapies for oncology. Recent FDA approvals and breakthroughs in these areas highlight the company's commitment to developing life-saving treatments for patients with limited or no treatment options.

The upcoming Q3 2025 financial results will be crucial in understanding BOS's progress in these areas and its ability to capitalize on the growing demand for precision-guided and personalized therapies.

For more information on BOS's Q3 2025 financial results and the earnings call, please visit the company's website at [boscom.com](https://boscom.com).